These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 26819308)

  • 1. A Hepatitis C Virus Envelope Polymorphism Confers Resistance to Neutralization by Polyclonal Sera and Broadly Neutralizing Monoclonal Antibodies.
    Wasilewski LN; El-Diwany R; Munshaw S; Snider AE; Brady JK; Osburn WO; Ray SC; Bailey JR
    J Virol; 2016 Jan; 90(7):3773-82. PubMed ID: 26819308
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Broadly Neutralizing Antibodies Targeting New Sites of Vulnerability in Hepatitis C Virus E1E2.
    Colbert MD; Flyak AI; Ogega CO; Kinchen VJ; Massaccesi G; Hernandez M; Davidson E; Doranz BJ; Cox AL; Crowe JE; Bailey JR
    J Virol; 2019 Jul; 93(14):. PubMed ID: 31068427
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extra-epitopic hepatitis C virus polymorphisms confer resistance to broadly neutralizing antibodies by modulating binding to scavenger receptor B1.
    El-Diwany R; Cohen VJ; Mankowski MC; Wasilewski LN; Brady JK; Snider AE; Osburn WO; Murrell B; Ray SC; Bailey JR
    PLoS Pathog; 2017 Feb; 13(2):e1006235. PubMed ID: 28235087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Escape of Hepatitis C Virus from Epitope I Neutralization Increases Sensitivity of Other Neutralization Epitopes.
    Gu J; Hardy J; Boo I; Vietheer P; McCaffrey K; Alhammad Y; Chopra A; Gaudieri S; Poumbourios P; Coulibaly F; Drummer HE
    J Virol; 2018 May; 92(9):. PubMed ID: 29467319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Broad Anti-Hepatitis C Virus (HCV) Antibody Responses Are Associated with Improved Clinical Disease Parameters in Chronic HCV Infection.
    Swann RE; Cowton VM; Robinson MW; Cole SJ; Barclay ST; Mills PR; Thomson EC; McLauchlan J; Patel AH
    J Virol; 2016 May; 90(9):4530-4543. PubMed ID: 26912610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Recombinant Hepatitis C Virus Genotype 1a E1/E2 Envelope Glycoprotein Vaccine Elicits Antibodies That Differentially Neutralize Closely Related 2a Strains through Interactions of the N-Terminal Hypervariable Region 1 of E2 with Scavenger Receptor B1.
    Johnson J; Freedman H; Logan M; Wong JAJ; Hockman D; Chen C; He J; Beard MR; Eyre NS; Baumert TF; Tyrrell DL; Law JLM; Houghton M
    J Virol; 2019 Nov; 93(22):. PubMed ID: 31462563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Diverse Panel of Hepatitis C Virus Glycoproteins for Use in Vaccine Research Reveals Extremes of Monoclonal Antibody Neutralization Resistance.
    Urbanowicz RA; McClure CP; Brown RJ; Tsoleridis T; Persson MA; Krey T; Irving WL; Ball JK; Tarr AW
    J Virol; 2015 Dec; 90(7):3288-301. PubMed ID: 26699643
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Defining Breadth of Hepatitis C Virus Neutralization.
    Kinchen VJ; Bailey JR
    Front Immunol; 2018; 9():1703. PubMed ID: 30116237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic anti-HCV broadly neutralizing human monoclonal antibodies with independent mechanisms.
    Mankowski MC; Kinchen VJ; Wasilewski LN; Flyak AI; Ray SC; Crowe JE; Bailey JR
    Proc Natl Acad Sci U S A; 2018 Jan; 115(1):E82-E91. PubMed ID: 29255018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Novel Approach To Display Structural Proteins of Hepatitis C Virus Quasispecies in Patients Reveals a Key Role of E2 HVR1 in Viral Evolution.
    Tong Y; Li Q; Li R; Xu Y; Pan Y; Niu J; Zhong J
    J Virol; 2020 Aug; 94(17):. PubMed ID: 32554700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis C virus resistance to broadly neutralizing antibodies measured using replication-competent virus and pseudoparticles.
    Wasilewski LN; Ray SC; Bailey JR
    J Gen Virol; 2016 Nov; 97(11):2883-2893. PubMed ID: 27667373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis C Virus Escape Studies of Human Antibody AR3A Reveal a High Barrier to Resistance and Novel Insights on Viral Antibody Evasion Mechanisms.
    Velázquez-Moctezuma R; Galli A; Law M; Bukh J; Prentoe J
    J Virol; 2019 Feb; 93(4):. PubMed ID: 30487284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A laboratory-adapted HCV JFH-1 strain is sensitive to neutralization and can gradually escape under the selection pressure of neutralizing human plasma.
    Song H; Ren F; Li J; Shi S; Yan L; Gao F; Li K; Zhuang H
    Virus Res; 2012 Oct; 169(1):154-61. PubMed ID: 22846920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel neutralizing human monoclonal antibody broadly abrogates hepatitis C virus infection in vitro and in vivo.
    Desombere I; Mesalam AA; Urbanowicz RA; Van Houtte F; Verhoye L; Keck ZY; Farhoudi A; Vercauteren K; Weening KE; Baumert TF; Patel AH; Foung SKH; Ball J; Leroux-Roels G; Meuleman P
    Antiviral Res; 2017 Dec; 148():53-64. PubMed ID: 29074219
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant hepatitis C virus envelope glycoprotein vaccine elicits antibodies targeting multiple epitopes on the envelope glycoproteins associated with broad cross-neutralization.
    Wong JA; Bhat R; Hockman D; Logan M; Chen C; Levin A; Frey SE; Belshe RB; Tyrrell DL; Law JL; Houghton M
    J Virol; 2014 Dec; 88(24):14278-88. PubMed ID: 25275133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Limited naturally occurring escape in broadly neutralizing antibody epitopes in hepatitis C glycoprotein E2 and constrained sequence usage in acute infection.
    Rodrigo C; Walker MR; Leung P; Eltahla AA; Grebely J; Dore GJ; Applegate T; Page K; Dwivedi S; Bruneau J; Morris MD; Cox AL; Osburn W; Kim AY; Schinkel J; Shoukry NH; Lauer GM; Maher L; Hellard M; Prins M; Luciani F; Lloyd AR; Bull RA;
    Infect Genet Evol; 2017 Apr; 49():88-96. PubMed ID: 28065804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Naturally selected hepatitis C virus polymorphisms confer broad neutralizing antibody resistance.
    Bailey JR; Wasilewski LN; Snider AE; El-Diwany R; Osburn WO; Keck Z; Foung SK; Ray SC
    J Clin Invest; 2015 Jan; 125(1):437-47. PubMed ID: 25500884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Applying antibody-sensitive hypervariable region 1-deleted hepatitis C virus to the study of escape pathways of neutralizing human monoclonal antibody AR5A.
    Velázquez-Moctezuma R; Law M; Bukh J; Prentoe J
    PLoS Pathog; 2017 Feb; 13(2):e1006214. PubMed ID: 28231271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The core domain of hepatitis C virus glycoprotein E2 generates potent cross-neutralizing antibodies in guinea pigs.
    Vietheer PT; Boo I; Gu J; McCaffrey K; Edwards S; Owczarek C; Hardy MP; Fabri L; Center RJ; Poumbourios P; Drummer HE
    Hepatology; 2017 Apr; 65(4):1117-1131. PubMed ID: 27997681
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Virus-Like Particles Containing the E2 Core Domain of Hepatitis C Virus Generate Broadly Neutralizing Antibodies in Guinea Pigs.
    McGregor J; Hardy JM; Lay CS; Boo I; Piontek M; Suckow M; Coulibaly F; Poumbourios P; Center RJ; Drummer HE
    J Virol; 2022 Mar; 96(5):e0167521. PubMed ID: 34986001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.